• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Immunovaccine’s targeted ovarian cancer therapy wins orphan drug status in EU

November 22, 2016 By Sarah Faulkner

ImmunovaccineImmunovaccine Inc. said today that the European Medicines Agency granted orphan drug designation for its immunotherapy candidate for ovarian cancer in the EU.

Orphan drug designation is granted to medicines intended for disease with a prevalence no greater than 5 in 10,000 people. According to the Nova Scotia-based company, ovarian cancer affects 3 per 10,000 people in the European Union or 15,000 women at any given time.

Immunovaccine’s therapy, DPX-Survivac, activates an immune response to a compound known as survivin – a protein found in more than 90% of ovarian cancer patients’ tumors. Survivin is also involved in pathways for cancer cell growth and survival.

The designation is one of several milestones for the company’s ovarian cancer program. Immunovaccine said in August that in a Phase I/Ib clinical trial, its DPX-Survivac was well tolerated with no serious adverse events and that the therapy initiated a sustained immune response.

DPX-Survivac won Fast Track status from the FDA 2 years as a maintenance therapy for patients with advanced ovarian, fallopian tube and peritoneal cancer. The U.S. federal watchdog also granted orphan drug status to the company’s candidate for the treatment of ovarian cancer, no matter the stage of progression.

“As our recent clinical program has demonstrated, ovarian cancer – one of the most underserved cancers in today’s treatment landscape – is a strong focus for Immunovaccine and, in particular, our DPX-Survivac program,” chief medical officer Dr. Gabriela Rosu said in prepared remarks. “We plan to leverage this important designation as we continue evaluating DPX-Survivac, with the goal of bringing a new option to patients fighting this disease.”

Filed Under: Business/Financial News, Clinical Trials, Featured, Food & Drug Administration (FDA), Immunotherapy, Oncology, Regulatory/Compliance, Women's Health Tagged With: Immunovaccine Inc.

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS